Abstract
In 2020, life expectancy in the United States decreased by an estimated 1.5 years. Due to mortality displacement during the COVID-19 pandemic, life expectancy could soon rebound to above its pre-pandemic baseline. We estimated the size and duration of this anticipated rise in life expectancy through 2030. We found that this rebound could persist for years and will likely be most pronounced in minority populations who suffered the highest rates of mortality during the pandemic. Accounting for this artificial rebound will be critical to avoid funneling resources away from populations that still urgently need them.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has been funded (in part) by contract 200-2016-91779 with the Centers for Disease Control and Prevention. The findings, conclusions, and views expressed are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project did not involve human or animal subjects and so was exempt from IRB requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.